Published in Antiviral Res on March 01, 1986
Picornaviruses. Curr Top Microbiol Immunol (2010) 1.53
cis-Bis[(1-adamantylmeth-yl)amine-κN]-dichloridoplatinum(II) N,N-dimethyl-formamide solvate. Acta Crystallogr Sect E Struct Rep Online (2009) 0.81
Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. J Clin Transl Hepatol (2015) 0.77
Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virol J (2010) 0.77
Effect of ribavirin on hepatitis A virus replication in vitro. Can J Infect Dis (1992) 0.76
Suppression of La antigen exerts potential antiviral effects against hepatitis A virus. PLoS One (2014) 0.76
Inhibitory effects of atropine, protamine, and their combination on hepatitis A virus replication in PLC/PRF/5 cells. Antimicrob Agents Chemother (1990) 0.75
A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol (1999) 2.99
Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol (1992) 2.74
Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother (1977) 2.71
The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol (2000) 2.55
Trisodium phosphonoformate, a new antiviral compound. Science (1978) 2.13
Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther (1982) 2.04
Inhibition of HTLV-III/LAV replication by foscarnet. Biochem Pharmacol (1985) 1.97
HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. Scand J Infect Dis (1978) 1.95
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology (1993) 1.92
Incidence of soccer injuries and their relation to training and team success. Am J Sports Med (1983) 1.88
A study of Australia-antigen-positive blood donors and their recipients, with special reference to liver histology. N Engl J Med (1972) 1.85
Identification of the in vitro translation products of adenovirus mRNA by immunoprecipitation. J Virol (1975) 1.74
Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother (1986) 1.71
Dane particles, DNA polymerase, and e-antigen in two different categories of hepatitis B antigen carriers. Intervirology (1975) 1.70
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1995) 1.69
Beta-blockers and lipid metabolism. Br Med J (1977) 1.68
Australia antigen and antibody in 10,000 Danish blood-donors. Lancet (1971) 1.63
[There is no reason to avoid calcium antagonists in hypertension]. Lakartidningen (1996) 1.62
Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat. A possible cause of the vaso-vagal reaction. Acta Physiol Scand (1972) 1.61
Effects of warming up, massage, and stretching on range of motion and muscle strength in the lower extremity. Am J Sports Med (1983) 1.58
Replication of poliovirus RNA studied by gel filtration and electrophoresis. Eur J Biochem (1969) 1.58
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol (2000) 1.55
Infection with delta agent in Sweden: introduction of a new hepatitis agent. J Infect Dis (1982) 1.55
Biochemical and biological characteristics of carbethoxylated poliovirus and viral RNA. Biochim Biophys Acta (1970) 1.54
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Chronic liver disease in Ethiopia: a clinical study with emphasis on identifying common causes. Ethiop Med J (1992) 1.52
RNA ligase activity in phage-infected bacteria and animal cells. Eur J Biochem (1974) 1.50
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Infection with the delta agent in chronic HBsAg carriers. Gastroenterology (1981) 1.48
Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun (1991) 1.44
Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period. J Intern Med (1992) 1.44
Binding of histidine to tobacco mosaic virus RNA. Biochem Biophys Res Commun (1972) 1.40
Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data. Am J Epidemiol (1986) 1.39
Intra- and inter-tester reliability and reference values for hand strength. J Rehabil Med (2001) 1.37
Antiherpetic activity and mechanism of action of 9-(4-hydroxybutyl)guanine. Antiviral Res (1983) 1.35
Replicative structures of poliovirus RNA in vivo. J Mol Biol (1971) 1.35
Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta (1980) 1.34
Epidemiology of genital herpes infections in Sweden. Acta Derm Venereol (1990) 1.34
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
Characteristics of herpesvirus mutants resistant to phosphonoformate and phosphonoacetate. Antimicrob Agents Chemother (1979) 1.31
Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J Med Virol (1996) 1.31
PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob Agents Chemother (1986) 1.30
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
PCR for the diagnosis of enteroviral meningitis. Scand J Infect Dis (1994) 1.29
Inhibition of the reverse transcriptase from HIV by 3'-azido-3'-deoxythymidine triphosphate and its threo analogue. Antiviral Res (1987) 1.29
The COPE index--a first stage assessment of negative impact, positive value and quality of support of caregiving in informal carers of older people. Aging Ment Health (2003) 1.28
Presence and persistence of Australia antigen among drug addicts. Vox Sang (1971) 1.26
Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. J Med Virol (1994) 1.26
Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs. Arch Virol (1978) 1.26
In vivo and in vitro synthesis of adenovirus type 2 early proteins. J Virol (1976) 1.26
Clinical aspects of delta infection. Br Med J (Clin Res Ed) (1983) 1.25
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Human papillomavirus DNA in urine samples compared with that in simultaneously collected urethra and cervix samples. J Clin Microbiol (1993) 1.24
Improved technique for detecting Australia antigen by immunoelectroosmophoresis. Vox Sang (1971) 1.24
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 1.24
Mother-to-infant transmission of hepatitis C virus. Ann Intern Med (1992) 1.23
Phosphonoformate inhibits reverse transcriptase. J Gen Virol (1979) 1.22
Studies on left ventricular receptors, signalling in non-medullated vagal afferents. Acta Physiol Scand (1972) 1.21
Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs. Antimicrob Agents Chemother (1978) 1.20
The relationship between active constriction and passive recoil of the veins at various distending pressures. Acta Physiol Scand (1968) 1.19
9-(3,4-dihydroxybutyl)guanine, a new inhibitor of herpesvirus multiplication. Antimicrob Agents Chemother (1983) 1.18
Acute hepatitis A, B and non-A, non-B in a Swedish community studied over a ten-year period. Scand J Infect Dis (1982) 1.18
Water intoxication associated with non-steroidal anti-inflammatory drug therapy. Acta Med Scand (1987) 1.18
Inhibition of cytomegalovirus late antigens by phosphonoformate. Intervirology (1980) 1.15
Mixed infection with two types of hepatitis C virus is probably a rare event. Infection (2000) 1.15
Lower extremity goniometric measurements: a study to determine their reliability. Arch Phys Med Rehabil (1982) 1.14
Decline of herpes simplex virus type 2 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. Scand J Infect Dis (1995) 1.14
Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods (1994) 1.14
The incidence and aetiology of respiratory tract infections in general practice--with emphasis on Mycoplasma pneumoniae. Infection (1976) 1.13
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother (1989) 1.13
Human papillomavirus infection of the male diagnosed by Southern-blot hybridization and polymerase chain reaction: comparison between urethra samples and penile biopsy samples. J Med Virol (1991) 1.11
Descriptions of functioning and health and relations to a gross motor classification in adults with cerebral palsy. Disabil Rehabil (2004) 1.11
Reversible inhibition of cellular metabolism by ribavirin. Antimicrob Agents Chemother (1978) 1.11
Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. J Infect Dis (1982) 1.10
Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol (1997) 1.09
Purification and characterization of an early protein (E14K) from adenovirus type 2-infected cells. J Virol (1978) 1.09
Vasoconstrictor fibre discharge to skeletal muscle, kidney, intestine and skin at varying levels of arterial baroreceptor activity in the cat. Acta Physiol Scand (1972) 1.09
Kinetic analysis in cell culture of the reversal of antiherpes activity of nucleoside analogs by thymidine. Antimicrob Agents Chemother (1983) 1.09
Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology (1993) 1.08
Typing of human papillomaviruses by consensus polymerase chain reaction and a non-radioactive reverse dot blot hybridization. J Virol Methods (1994) 1.07
Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. J Med Virol (1991) 1.06
Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine. Antimicrob Agents Chemother (1985) 1.04
Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr (1991) 1.04
Overall cardiovascular regulation. Annu Rev Physiol (1976) 1.02
Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology (1980) 1.02
Antiherpes activity of [E]-5-(1-propenyl)-2'-deoxyuridine and 5-(1-propenyl)-1-beta-D-arabinofuranosyluracil. Antiviral Res (1981) 1.02
Hepatitis E virus infection in pregnancy in Ethiopia. Ethiop Med J (1993) 1.01